MX2022013883A - Compuestos de metiltioninio para uso en el tratamiento de covid-19. - Google Patents
Compuestos de metiltioninio para uso en el tratamiento de covid-19.Info
- Publication number
- MX2022013883A MX2022013883A MX2022013883A MX2022013883A MX2022013883A MX 2022013883 A MX2022013883 A MX 2022013883A MX 2022013883 A MX2022013883 A MX 2022013883A MX 2022013883 A MX2022013883 A MX 2022013883A MX 2022013883 A MX2022013883 A MX 2022013883A
- Authority
- MX
- Mexico
- Prior art keywords
- methylthioninium
- compounds
- covid
- treatment
- subject
- Prior art date
Links
- CJYMGANFUNYUNB-UHFFFAOYSA-N 2-methylthionine Chemical class CC1=CC=CC=CC=CS1 CJYMGANFUNYUNB-UHFFFAOYSA-N 0.000 title abstract 2
- 208000025721 COVID-19 Diseases 0.000 title abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención proporciona métodos para tratar COVID-19 en un sujeto usando compuestos de metiltioninio.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2006659.3A GB202006659D0 (en) | 2020-05-05 | 2020-05-05 | Therapeutic treatments |
| GBGB2016955.3A GB202016955D0 (en) | 2020-10-26 | 2020-10-26 | Therapeutic treatments |
| PCT/EP2021/061480 WO2021224144A1 (en) | 2020-05-05 | 2021-04-30 | Methylthioninium compounds for use in the treatment of covid-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022013883A true MX2022013883A (es) | 2022-11-30 |
Family
ID=75801589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013883A MX2022013883A (es) | 2020-05-05 | 2021-04-30 | Compuestos de metiltioninio para uso en el tratamiento de covid-19. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230165875A1 (es) |
| EP (1) | EP4146223A1 (es) |
| JP (1) | JP2023525512A (es) |
| KR (1) | KR20230012514A (es) |
| CN (1) | CN116056724A (es) |
| AU (1) | AU2021267670A1 (es) |
| BR (1) | BR112022022515A2 (es) |
| CA (1) | CA3181393A1 (es) |
| MX (1) | MX2022013883A (es) |
| TW (1) | TW202200150A (es) |
| WO (1) | WO2021224144A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202204185D0 (en) * | 2022-03-24 | 2022-05-11 | Wista Lab Ltd | Oral treatment |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060264423A1 (en) | 2005-05-20 | 2006-11-23 | Bioenvision, Inc. | Methylene Blue Therapy of Viral Disease |
| PL2013191T6 (pl) | 2006-03-29 | 2019-07-31 | Wista Laboratories Ltd. | Sole 3,7-diamino-10H-fenotiazynowe i ich zastosowanie |
| CA2827027C (en) | 2011-02-11 | 2019-06-04 | Wista Laboratories Ltd. | Phenothiazine diaminium salts and their use |
| WO2020020751A1 (en) * | 2018-07-26 | 2020-01-30 | Wista Laboratories Ltd. | Optimised dosage of diaminophenothiazines in populations |
-
2021
- 2021-04-30 JP JP2022567230A patent/JP2023525512A/ja active Pending
- 2021-04-30 MX MX2022013883A patent/MX2022013883A/es unknown
- 2021-04-30 BR BR112022022515A patent/BR112022022515A2/pt not_active Application Discontinuation
- 2021-04-30 CA CA3181393A patent/CA3181393A1/en active Pending
- 2021-04-30 CN CN202180043773.6A patent/CN116056724A/zh active Pending
- 2021-04-30 US US17/997,758 patent/US20230165875A1/en active Pending
- 2021-04-30 AU AU2021267670A patent/AU2021267670A1/en not_active Abandoned
- 2021-04-30 WO PCT/EP2021/061480 patent/WO2021224144A1/en unknown
- 2021-04-30 EP EP21723699.1A patent/EP4146223A1/en not_active Withdrawn
- 2021-04-30 KR KR1020227042294A patent/KR20230012514A/ko active Pending
- 2021-05-05 TW TW110116179A patent/TW202200150A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230165875A1 (en) | 2023-06-01 |
| AU2021267670A1 (en) | 2022-12-08 |
| CA3181393A1 (en) | 2021-11-11 |
| CN116056724A (zh) | 2023-05-02 |
| JP2023525512A (ja) | 2023-06-16 |
| WO2021224144A1 (en) | 2021-11-11 |
| EP4146223A1 (en) | 2023-03-15 |
| BR112022022515A2 (pt) | 2022-12-13 |
| TW202200150A (zh) | 2022-01-01 |
| KR20230012514A (ko) | 2023-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021552497A1 (en) | Enzyme inhibitors | |
| MX2021010193A (es) | Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales. | |
| ZA201907052B (en) | N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | |
| PH12021551689A1 (en) | Cgrp antagonists for treating migraine breakthrough | |
| ZA202001717B (en) | Compounds, salts thereof and methods for treatment of diseases | |
| MX2019007256A (es) | Inhibidores de las fosfodiesterasas y métodos de tratamiento microbiano. | |
| MX2023008193A (es) | Procedimientos para tratar el cáncer. | |
| MX2023013912A (es) | Metodos para inhibir ras. | |
| PH12022550130A1 (en) | Enzyme inhibitors | |
| MX2021003903A (es) | Terapia combinada para el melanoma. | |
| MX2020008195A (es) | Compuestos para el tratamiento del dolor. | |
| TN2019000211A1 (en) | Antitumoral compounds | |
| MX2021006011A (es) | Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma. | |
| PH12018502297A1 (en) | 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (uti) treatment | |
| MX2020012291A (es) | Compuestos para el tratamiento de cancer de mama triple negativo y cancer de ovario. | |
| PH12022550118A1 (en) | Enzyme inhibitors | |
| PH12021552135A1 (en) | Methods of treating al amyloidosis | |
| CA227900S (en) | Skin treatment equipment | |
| PH12018501943A1 (en) | Pharmaceutical compositions for the treatment of cancer | |
| MX2021009863A (es) | Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer. | |
| PH12022550114A1 (en) | Methods of treating or preventing spinal muscular atrophy | |
| MX2020003270A (es) | Combinacion de un inhibidor de btk y un inhibidor de cdk9 para tratar el cancer. | |
| JOP20210216A1 (ar) | علاج السرطان | |
| PH12021552499A1 (en) | Methods for the treatment of beta-thalassemia | |
| MX2021011799A (es) | Antagonistas de semaforina 4d para usarlos en la terapia contra el cancer. |